Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > April 12, 2024
Daily News
April 12, 2024
- Wholesaler Purchase Prices of Unprofitable Drugs on Upward Trend after FY2024 Revision
April 12, 2024
- Japan Autoimmune Drug Market Likely to Top 1 Trillion Yen in 2033: Fuji Keizai
April 12, 2024
- Smallpox Drug TPOXX Filed in Japan after Govt Request
April 12, 2024
- Japan Will Persistently Urge China to Release Detained Astellas Employee: Govt
April 12, 2024
- Moderna, Tohoku Biobank Start Epidemiology Study on Latent Viruses
April 12, 2024
- ASKA’s Birth Control Pill Makes Mark in Japan PIII Study
April 12, 2024
Japan is finally launching technical discussions on its cost-effectiveness assessment (CEA) system. A health ministry-funded research group is set to…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…